Citigroup
APLS

Citigroup’s Apellis Pharmaceuticals APLS Stock Holding History

Citigroup’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-60,000
Closed -$2.41M – 5710
2026
Q1 		$2.41M Buy
+60,000
New +$1.29M ﹤0.01% 2550
2025
Q1 		– Sell
-29,000
Closed -$925K – 5555
2024
Q4 		$925K Buy
+29,000
New +$872K ﹤0.01% 3420
2024
Q2 		– Sell
-89,700
Closed -$5.27M – 5570
2024
Q1 		$5.27M Buy
+89,700
New +$5.72M ﹤0.01% 1675
2023
Q4 		– Sell
-30,000
Closed -$1.14M – 5683
2023
Q3 		$1.14M Buy
30,000
+28,400
+1,775% +$1.25M ﹤0.01% 2398
2023
Q2 		$146K Sell
1,600
-23,300
-94% -$2.01M ﹤0.01% 4052
2023
Q1 		$1.64M Buy
24,900
+200
+0.8% +$11.5K ﹤0.01% 2158
2022
Q4 		$1.28M Sell
24,700
-10,300
-29% -$546K ﹤0.01% 2399
2022
Q3 		$2.39M Buy
+35,000
New +$2.07M ﹤0.01% 2023

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's APLS Position: Q2 2026 in Review

Citigroup sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 657,223 shares — an estimated $26.4M sold.

Citigroup first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $26.4M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Citigroup reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 657,223 Apellis Pharmaceuticals shares in Q2 2026, an estimated $26.4M.
  • Citigroup first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
  • Citigroup's Apellis Pharmaceuticals position peaked at $26.4M in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.